BioPerfectus Highlights Diagnostic Solutions for HPV & Cervical Cancer Screening, STIs and Vector-Borne Diseases
|
By LabMedica International staff writers Posted on 05 Feb 2024 |

Jiangsu Bioperfectus Technologies Co., Ltd. (Shanghai, China) is showcasing its range of diagnostics solutions for HPV and cervical cancer screening, sexually transmitted infections (STIs), and vector-borne diseases at Medlab Middle East 2024 that offer dependable, high-throughput, and cost-effective results.
BioPerfectus provides diagnostic solutions for STIs, including asymptomatic screening and clinical diagnosis. The key features of the company’s clinical STI testing technologies are adaptability and reliable outcomes. BioPerfectus’ products for STI asymptomatic screening, include the SAW-48 automated nucleic acid extraction workstation, the STC-96A PLUS Real-Time PCR system, nucleic acid extraction rapid kit, N. Gonorrhoeae / Chlamydia Trachomatis / U.urealyticum Real-Time PCR Kit, and STC auto interpretation software. In addition, BioPerfectus is highlighting its CE-marked PCR assays for STI clinical diagnostics such as Herpes Simplex Virus Real-Time PCR Kit, Herpes Simplex Virus Type I II Real-Time PCR Kit, Mycoplasma Genitalium Real-Time PCR Kit, Mycoplasma Hominis Real-Time PCR Kit, Trichomonas Vaginalis Real-Time PCR Kit and Treponema Pallidum Real-Time PCR Kit.
At Medlab Middle East 2024, BioPerfectus is showcasing its comprehensive range of diagnostic solutions essential for timely infectious disease control when outbreaks occur, including Vibrio Cholerae Real-Time PCR Kit, Monkeypox Virus Real-Time PCR Kit, Zika Virus / Dengue Virus / Chikungunya Virus Real-Time PCR Kit and Ebola Virus Real-Time PCR Kit. Visitors to the BioPerfectus booth at Medlab Middle East 2024 can experience the SAW-48 automated nucleic acid extraction workstation which is now lighter, smaller, and faster. Offering seamless workflow, it allows labs to go from the primary sample tube to a PCR ready-to-go tube in just one step, and say goodbye to time-consuming and complex processes.
Additionally, SAW-48 is compatible with various types of sample tubes and a diverse range of extraction and PCR reagents, making it the ideal choice for a wide spectrum of infectious disease diagnostic applications. In addition, BioPerfectus is highlighting the SSNP-2000B nucleic acid extraction system which integrates new technologies such as machine, electricity, and computer software to enable automatic nucleic acid extraction of 32 samples at one time. Alongside, BioPerfectus is presenting the STC-96A Plus Real-Time PCR system which is a more-than-ever flexible, efficient, and reliable breakthrough in the real-time PCR analysis of gene expression and genetic variation. It allows laboratories to apply two different PCR assays on just one instrument with separate controlled programs.
Related Links:
Jiangsu Bioperfectus Technologies Co., Ltd.
Latest Medlab 2024 News
- Anbio Biotechnology Presents Point-Of-Care IVD Solutions
- 77 Elektronika Showcases Latest Developments in Urinalysis
- BioVendor Group Unveils Latest Innovations in Immunodiagnostics and Molecular Diagnostics
- Sansure Presents Future of Pathogen Identification and Disease Diagnosis
- Spinreact Presents Latest Developments in IVD
- Alifax Demonstrates Automated Solutions to Improve Performance in Laboratory Settings
- YHLO Unveils New iBC 900 Automated Chemistry Analyzer
- Lifotronic Demonstrates Latest Medical Innovations in Disease Diagnostics
- Dymind Introduces New High-End Hematology Analyzer with Innovative Functions
- DIRUI Exhibits Latest Lab Automation Technologies and Devices
- Beckman Coulter Unveils DxC 500 AU Chemistry Analyzer
- Boule Presents Next Generation Hematology and Clinical Chemistry Systems
- bioMérieux Showcases Advanced Generation of VIDAS Immunoassay Solution
- Mindray Showcases Range of Advanced Total IVD Solutions
- Medlab Middle East 2024 Provides a Peek into the Laboratory of the Future
Channels
Clinical Chemistry
view channel
Portable Troponin Assay Brings Heart Attack Diagnosis Closer to Patients
Timely confirmation of myocardial infarction often depends on laboratory testing that may not be immediately available at the point of care. This gap between clinical suspicion and definitive evidence... Read more
Blood Biomarker Reveals Hidden Disability Progression in Multiple Sclerosis
Multiple sclerosis (MS) remains difficult to monitor because neurological decline can continue even after relapses stop. This progression independent of relapse activity is often subtle and may escape... Read moreMolecular Diagnostics
view channel
Blood Test Could Help Fast-Track Lymphoma Diagnosis in Resource-Limited Settings
Lymphoma can be difficult to distinguish from infections and benign conditions, while definitive diagnosis often depends on surgical tissue sampling and specialized pathology that may not be readily available.... Read more
Liquid Biopsy Assay Enriches Tumor DNA for Early Detection and Monitoring
Circulating tumor-derived DNA (ctDNA) is often present at very low levels in plasma, making cancer detection and monitoring through liquid biopsy technically challenging. Background cell-free DNA from... Read moreHematology
view channel
New Genetic Findings Reveal Cause of Bone Marrow Failure Syndrome
Inherited bone marrow failure syndromes (IBMFS) impair the bone marrow’s ability to produce sufficient healthy blood cells and are associated with an increased risk of early-onset myelodysplastic syndromes (MDS).... Read more
Ultra-Portable Device Enables Finger-Prick Blood Testing at Home
Patients who need frequent blood tests often face repeated clinic visits that burden services and disrupt care. In the UK, millions of tests are performed each year to diagnose disease, guide therapy,... Read moreImmunology
view channel
Study Reveals Viral Protein Driving COVID-19-Related Vascular Injury
Lingering symptoms after acute COVID-19 infection remain a clinical challenge, with many patients experiencing fatigue, cognitive problems, and cardiovascular complications months later.... Read more
Study Reveals Immune Mechanism Driving Severe COVID-19 Progression
Severe COVID-19 has highlighted gaps in understanding of early antiviral responses, particularly why some patients deteriorate despite timely care. Type I interferons are central to host defense, yet their... Read more
Antibody Profiling Identifies Preclinical Inflammatory Bowel Disease Years Before Diagnosis
Inflammatory bowel disease often develops after a prolonged symptom-free period, complicating timely recognition and clinical intervention. Limited understanding of immune activity during this silent phase... Read moreMicrobiology
view channel
Precision Screening Helps Close Hepatitis C Diagnosis and Treatment Gaps
Hepatitis C remains a leading cause of cirrhosis and liver cancer, yet many infections go undiagnosed or untreated because health systems fail to reach those at greatest risk. Although highly effective... Read moreProteomic Workflow Maps Microbial and Host Responses in Intestinal Inflammation
The intestinal microbiome influences digestion, metabolism, and immunity, yet its complexity makes functional measurements difficult to obtain. DNA surveys can indicate which organisms and potential pathways... Read more
Metagenomic Sequencing Enables Faster Diagnosis of Respiratory Infections in Cystic Fibrosis
Serious lung infections remain a major cause of morbidity among people with cystic fibrosis, a life-threatening genetic disorder characterized by persistent airway colonization and frequent antimicrobial exposure.... Read morePathology
view channel
FDA-Cleared Digital Pathology Platform Expands Interoperability for Primary Diagnosis
Rising cancer incidence is colliding with a shrinking pathologist workforce, intensifying pressure on diagnostic turnaround times in clinical laboratories. Many labs are adopting digital pathology to manage... Read more
AI Pathology Tool Predicts Relapse Risk in Stage II Colorectal Cancer
Bowel cancer is Australia’s fourth most commonly diagnosed cancer and the second leading cause of cancer death, while remaining the third most common cancer worldwide. In stage-two disease, determining... Read more
AI Pathology Tool Stratifies Rectal Cancer to Guide Chemoradiotherapy
Choosing intensified regimens for locally advanced rectal cancer is challenging because these therapies can cause serious side effects. Colorectal cancer is the fourth-most fatal cancer in the UK, and... Read more
PD-L1 Assay Guides Pembrolizumab Eligibility in Ovarian, Fallopian Tube, and Peritoneal Cancers
Agilent Technologies’ PD-L1 IHC 22C3 pharmDx (Code SK006) has received European Union certification as a companion diagnostic to aid in identifying patients with epithelial ovarian, fallopian tube, or... Read moreTechnology
view channel
Interoperable Data Platform Standardizes Multi-Cancer Blood Test Results
Proteotype Diagnostics has introduced Alchemi, a proprietary data and clinical workflow platform being developed for Enlighten, the company’s investigational blood-based multi-cancer test.... Read more
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channel
Standardized Staining Technology Advances Digital Pathology Workflows
Digital pathology is increasingly used to streamline cancer diagnostics, yet staining variability can hinder slide interpretation and limit the reliability of artificial intelligence tools.... Read more
Global Testing Service Advances Leukemia MRD Monitoring
KMT2A rearrangements drive aggressive subsets of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) and are associated with relapse and poor outcomes. As menin inhibitors enter clinical... Read more








